Media stories about Oncolytics Biotech (NASDAQ:ONCY) have trended somewhat positive on Sunday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Oncolytics Biotech earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.5897621302408 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Oncolytics Biotech (NASDAQ:ONCY) remained flat at $0.33 on Friday. The stock has a 50-day moving average price of $0.34 and a 200-day moving average price of $0.50. Oncolytics Biotech has a 52-week low of $0.24 and a 52-week high of $1.40.
ILLEGAL ACTIVITY NOTICE: “Oncolytics Biotech (NASDAQ:ONCY) Receives Daily Media Impact Score of 0.14” was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.truebluetribune.com/2017/09/17/oncolytics-biotech-oncy-getting-somewhat-positive-media-coverage-study-finds.html.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company’s clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials.
Receive News & Ratings for Oncolytics Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.